SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-012193
Filing Date
2021-02-26
Accepted
2021-02-26 17:10:42
Documents
3
Period of Report
2021-02-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea136652-8k_aditxtherap.htm 8-K 26468
2 EMPLOYMENT AGREEMENT, DATED FEBRUARY 24, 2021 ea136652ex10-1_aditxtherap.htm EX-10.1 59078
3 2021 OMNIBUS EQUITY INCENTIVE PLAN ea136652ex10-2_aditxtherap.htm EX-10.2 131655
  Complete submission text file 0001213900-21-012193.txt   218599
Mailing Address 2569 WYANDOTTE, ST. SUITE 101 MOUNTAIN CA 94043
Business Address 2569 WYANDOTTE, ST. SUITE 101 MOUNTAIN CA 94043 909-488-0844
Aditx Therapeutics, Inc. (Filer) CIK: 0001726711 (see all company filings)

IRS No.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39336 | Film No.: 21690943
SIC: 2834 Pharmaceutical Preparations